Klebsiella pneumoniae tetravalent bioconjugate vaccine - LimmaTech Biologics
Alternative Names: GSK-4429016; GSK-4429016A; Kleb4VLatest Information Update: 06 Feb 2024
At a glance
- Originator GlycoVaxyn
- Developer LimmaTech Biologics
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Klebsiella infections
Most Recent Events
- 06 Feb 2024 Discontinued - Phase-I/II for Klebsiella infections (In the elderly, Prevention, In volunteers, In adults) in Germany (IM)
- 26 Sep 2022 LimmaTech Biologics completes a phase I/II clinical trial in Klebsiella infections (In adults, In the elderly, In volunteers, Prevention) in Germany (IM) (EudraCT2020-005090-26)
- 21 Jun 2021 Phase-I/II clinical trials in Klebsiella infections (In adults, In the elderly, In volunteers, Prevention) in Germany (IM)